MoonLake Immunotherapeutics
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
On June 17, 2025, Dr. Jorge Santos da Silva, the Chief Executive Officer and a director of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c). Dr. Santos da Silva's plan provides for the sale, subject to certain conditions, of up to 200,000 Class A Ordinary Shares through November 24, 2025.
MoonLake Immunotherapeutics
On June 17, 2025, Mr. Matthias Bodenstedt, the Chief Financial Officer of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b-1(c). Dr. Bodenstedt's plan provides for the sale, subject to certain conditions, of up to 300,000 Class A Ordinary Shares through March 31, 2026.
On June 26, 2025, Dr. Kristian Reich, Chief Scientific Officer of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c). Dr. Reich’s plan provides for the sale, subject to certain conditions, of up to 300,000 Class A Ordinary Shares through March 31, 2026.
During the three months ended June 30, 2025, no other director or Section 16 officer of the Company adopted orterminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.